Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Healthcare company Organon & Co. (OGN) said on Wednesday that it is discontinuing the development of its investigational ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

Organon said on Wednesday it will the stop development of an experimental treatment it acquired through its purchase of Forendo Pharma, after the drug failed to reduce pelvic pain in women with ...

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Organon (NYSE:OGN) stock is in focus as the company halts OG-6219 development after a Phase 2 trial in endometriosis-related pain fails. Read more here.

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Organon said on Wednesday it will discontinue the development of its experimental drug, after it failed to reduce pain in women suffering from endometriosis in a mid-stage study.

In addition to causing pain that can become quite severe, endometriosis can also cause scar tissue and adhesions to develop that can distort a woman’s internal anatomy. In advanced stages, internal ...

March 13 (10 a.m. to 1 p.m. EST): Peritoneal Endometriosis and Pain March 20 (10 a.m. to 1 p.m. EST): Deeper Debilitating Disease and Its Definitive Treatment ...